Bayer and its billion-dollar problem! Evotec fails to impress analysts! AI stock NetraMark makes a splash!

NetraMark Holdings: Will a new customer trigger a breakout?

Artificial intelligence (AI) is playing an increasingly important role in the development of new drugs. The advantages are clear: it saves time and money. NetraMark specializes in AI-assisted clinical trials through its proprietary platform NetraAI, and is steadily expanding its client base. Just two days ago, the Company announced a new partnership: Asklepion Pharmaceuticals will use NetraAI to analyze its key Phase III paediatric clinical trial. The study is investigating the efficacy of intravenous L-citrulline (CIT-003-01) in preventing acute lung injury in children who require cardiopulmonary bypass surgery due to congenital heart defects.

NetraMark's AI analytics will help demonstrate the benefits of L-citrulline in specific patient subgroups and improve study results. Asklepion CEO Jeff Courtney commented: "We want to push the boundaries of drug development in paediatrics, and NetraMark's technology shows us a promising path forward."

NetraMark is thus continuing its positive development and positive news flow. Most recently, NetraAI caused a sensation when it outperformed major competitors ChatGPT and DeepSeek in a comparative evaluation. In three independent studies focused on schizophrenia, depression, and pancreatic cancer, NetraAI was the only system able to reliably identify clinically relevant subgroups.

Given these developments, it seems only a matter of time before the share, currently trading on Tradegate in Germany, breaks out of its sideways movement between EUR 0.80 and EUR 1.00 that has persisted since May. The price target set by analysts at Zacks Small-Cap Research is CAD 2.25.

Evotec: Share price falls again

Evotec shares continue to be a source of disappointment. The announced sale of peripheral businesses – or perhaps even crown jewels? – is now being implemented. Evotec recently announced a non-binding agreement with Sandoz regarding the possible sale of Just – Evotec Biologics EU, owner of the J.POD facility for the manufacture of biologics in Toulouse, France. Under the agreement, Sandoz would also acquire a technology license, thereby gaining access to Evotec's proprietary platform for the integrated development and advanced continuous manufacturing of biologics. The two companies have been working closely together at the Toulouse site since 2024.

The agreement is part of Evotec's new strategy to drive sustainable and profitable growth. The further development of Just – Evotec Biologics would thus be less capital-intensive for the German biotech company in the future. Evotec would receive around USD 300 million for the site. Additional technology-related considerations, future development revenues, milestone payments, and product license fees are also planned.

Evotec shares reacted positively to the news only briefly. They had been falling steadily over the previous six trading days. The share price is now back well below EUR 7.

Bayer: Billion-dollar lawsuits are back

Bayer shares have been one of the positive surprises on the DAX so far this year. The news flow from the pharmaceutical sector was positive, and the lawsuits in the US were ignored. Yesterday, this scenario took a hit, and investors sent the share price down by over 5%.

The reason was the second quarter report. Although the currency-adjusted annual forecast was raised just a few days ago, investors were not at all pleased with some of the details in the quarterly report. Special items resulted in a consolidated loss of around EUR 200 million. This is attributable to the ongoing proceedings in the US relating to glyphosate. The Leverkusen-based company had to set aside further provisions for this. Free cash flow also declined significantly, falling from EUR 1.27 billion to EUR 125 million.

The fact that adjusted profit rose significantly and net financial debt was reduced by 9.5% to EUR 33.3 billion did not deter investors from selling the stock. Analysts were also less than enthusiastic. By midday, Jefferies, JPMorgan, and UBS had confirmed their "Hold" recommendations.

Bayer has once again shown that the lawsuit issue could resurface at any time. This makes the Company difficult to assess. The news flow for NetraMark remains positive. This should soon catapult the share price out of its sideways movement. Evotec's new focus on profitability at the expense of growth continues to be unpopular with investors and analysts.